HC Wainwright Lifts Earnings Estimates for Beam Therapeutics

Key Points

• HC Wainwright modestly improved its earnings forecasts for Beam Therapeutics, revising its FY2026 loss estimate to $4.65 per share from $4.67. The company is still expected to post losses, including a projected $5.09-per-share loss in FY2027.
• Beam reported a quarterly loss of $1.28 per share, worse than the $1.17 consensus estimate, while revenue of $0.31 million fell short of the $8.75 million forecast and declined 96.8% year over year.
• Analyst opinions are mixed but lean positive: MarketBeat data shows a “Moderate Buy” consensus rating and an average price target of $47.36.

Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Equities researchers at HC Wainwright raised their FY2026 EPS estimates for Beam Therapeutics in a research note issued to investors on Friday, November 6th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($4.65) per share for the year, up from their previous estimate of ($4.67). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Beam Therapeutics' current full-year earnings is ($4.66) per share. HC Wainwright also issued estimates for Beam Therapeutics' Q4 2026 earnings at ($1.27) EPS, Q1 2027 earnings at ($1.23) EPS, Q2 2027 earnings at ($1.26) EPS, Q3 2027 earnings at ($1.21) EPS, Q4 2027 earnings at ($1.26) EPS, FY2027 earnings at ($5.09) EPS, FY2028 earnings at ($4.28) EPS, FY2029 earnings at ($2.95) EPS and FY2030 earnings at ($1.40) EPS.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported ($1.28) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.11). The company had revenue of $0.31 million for the quarter, compared to analyst estimates of $8.75 million. Beam Therapeutics had a negative return on equity of 32.76% and a negative net margin of 73.04%. Beam Therapeutics's revenue for the quarter was down 96.8% on a year-over-year basis. During the same period in the prior year, the business posted ($1.10) earnings per share.

BEAM has been the topic of several other reports. Wedbush raised their target price on Beam Therapeutics from $28.00 to $30.00 and gave the stock an "outperform" rating in a report on Wednesday, November 4th. Weiss Ratings reissued a "sell (d-)" rating on shares of Beam Therapeutics in a report on Thursday, October 15th. Guggenheim lowered their price objective on Beam Therapeutics from $55.00 to $51.00 and set a "buy" rating on the stock in a research report on Thursday, November 5th. Wall Street Zen cut shares of Beam Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, October 31st. Finally, Canaccord Genuity Group dropped their price objective on shares of Beam Therapeutics from $79.00 to $78.00 and set a "buy" rating on the stock in a research note on Wednesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $47.36.

Beam Therapeutics Trading Up 2.3%

Shares of BEAM stock opened at $27.02 on Tuesday. Beam Therapeutics has a 52-week low of $20.23 and a 52-week high of $38.26. The company has a debt-to-equity ratio of 0.11, a current ratio of 13.01 and a quick ratio of 14.57. The business has a 50-day simple moving average of $25.53 and a 200-day simple moving average of $28.00.

Hedge Funds Weigh In On Beam Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Fulcrum Asset Management LLP acquired a new stake in Beam Therapeutics in the third quarter valued at approximately $51,000. Allspring Global Investments Holdings LLC increased its position in shares of Beam Therapeutics by 4.2% in the third quarter. Allspring Global Investments Holdings LLC now owns 20,350 shares of the company's stock valued at $496,000 after buying an additional 815 shares in the last quarter. AlphaCentric Advisors LLC purchased a new stake in shares of Beam Therapeutics in the third quarter valued at approximately $350,000. Privium Fund Management B.V. raised its stake in shares of Beam Therapeutics by 29.9% during the 3rd quarter. Privium Fund Management B.V. now owns 91,282 shares of the company's stock worth $2,232,000 after buying an additional 21,000 shares during the period. Finally, Commonwealth Equity Services LLC raised its stake in shares of Beam Therapeutics by 32.2% during the 3rd quarter. Commonwealth Equity Services LLC now owns 11,132 shares of the company's stock worth $272,000 after buying an additional 2,712 shares during the period. Hedge funds and other institutional investors own 99.68% of the company's stock.

Insider Buying and Selling at Beam Therapeutics

In other news, CEO John Evans sold 25,000 shares of the stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $23.57, for a total transaction of $589,250.00. Following the sale, the chief executive officer directly owned 1,047,205 shares of the company's stock, valued at $24,682,621.85. This represents a 2.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 3.80% of the company's stock.

Beam Therapeutics News Roundup

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: HC Wainwright increased its estimates for Q4 2026 and FY2026, and lifted forecasts for each quarter of 2027 and FY2027. It also raised its FY2028–FY2030 estimates; for example, the FY2030 loss forecast improved to $1.40 per share from $1.48. The company is still expected to report losses, including a projected $5.09 per-share loss in FY2027, but the revised figures are less negative than before.

About Beam Therapeutics

Beam Therapeutics is a biotechnology company developing genetic medicines using base editing, a form of gene editing designed to make precise changes to DNA. Its platform includes base-editing technologies and delivery systems intended to address diseases by altering the genetic instructions involved in their development.

The company's research and development programs include potential treatments for genetic diseases, including sickle cell disease. Its work spans medicines made by editing a patient's cells outside the body as well as approaches intended to deliver gene editing directly to cells in the body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.